Hepatology

By reconstructing a fetal liver–specific niche, FLOs enable simultaneous development of hepatic and hematopoietic lineages, revealing cross-talk essential for understanding human liver development and immune injury.

AI-enhanced ECG screening uncovers silent liver cirrhosis, enabling earlier diagnosis and intervention in routine primary care.

A long-term study shows that recurrence beyond the Milan criteria, rather than recurrence itself, drives poorer survival after curative hepatocellular carcinoma resection.

Study shows DAAs and interferon offer similar long-term protection against hepatocellular carcinoma after hepatitis C cure and introduces a nomogram to predict 8-year HCC risk.

Phase II ELMWOOD trial shows elafibranor is well tolerated and improves liver biochemistry and pruritus in primary sclerosing cholangitis, supporting further trials.

A phase 2 trial finds tinengotinib demonstrates anti-tumour activity in previously treated advanced cholangiocarcinoma with FGFR alterations.

A new multinational study reports that rifaximin use in cirrhosis and hepatic encephalopathy is linked to significantly higher risks of antimicrobial resistance and severe infections.

Large PBC cohort shows current liver stiffness measurement >10 kPa predicts hepatic decompensation, outperforming biochemical response or LSM trajectory.